According to a report by Menafn on October 16th, biotechnology company 22nd Century Group has announced plans to publicly offer the sale of its common stock or alternative equivalents, as well as subscription warrants to purchase common stock. All common stock or equivalents, as well as subscription warrants, to be sold in the offering will be issued by 22nd Century Group.
Dawson James Securities has been appointed as the exclusive underwriter for this public offering. The company anticipates utilizing the net proceeds from this issuance for general corporate purposes.
According to reports, 22nd Century Group is a leading biotechnology company dedicated to improving health through advanced plant technologies utilizing reduced nicotine tobacco, cannabis/hemp, and hops. The company secured the first and only Modified Risk Tobacco Product (MRTP) authorization from the US Food and Drug Administration in December 2021 for its tobacco combustion product.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
